The nucleus accumbens is a major input structure of the basal ganglia and integrates
information from cortical and limbic structures to mediate goal-directed behaviors. Chronic …

Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …

The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a
promising new strategy with potential for developing novel treatments for a variety of central …

Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery,
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …

Glutamate is the primary excitatory neurotransmitter in the brain and plays critical roles in all
aspects of neuronal function. Disruption of normal glutamate transmission has been …

Major depression is a common, recurrent mental illness that affects millions of people
worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has …

Support for the N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis of
schizophrenia has led to increasing focus on restoring proper glutamatergic signaling as an …

Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat
psychosis, with all of the currently available antipsychotics acting through the antagonism of …

Heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptors (GPCRs)
can form multiprotein complexes (heteromers), which can alter the pharmacology and …

Schizophrenia is a common debilitating disease characterized by continuous or relapsing
episodes of psychosis. Although the molecular mechanisms underlying this psychiatric …